Keros Therapeutics Inc
NASDAQ:KROS
Operating Margin
Keros Therapeutics Inc
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Operating Margin Across Competitors
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| US |
|
Keros Therapeutics Inc
NASDAQ:KROS
|
585.6m USD |
-5 939%
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
-17 527%
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
344.2B USD |
29%
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
154.2B USD |
22%
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
130.2B USD |
38%
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
129.6B USD |
40%
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
-370%
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
121.6B AUD |
26%
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
65B USD |
30%
|
|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
-33%
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
34.6B EUR |
-1%
|
Keros Therapeutics Inc
Glance View
In the heart of the biotechnology sector lies Keros Therapeutics Inc., a company heralded for its innovative approach in addressing unfulfilled needs within hematological and musculoskeletal disorders. Established with a keen focus on advancing therapies derived from the Transforming Growth Factor-Beta (TGF-β) family of proteins, Keros aims to reshape the treatment landscape of complex diseases. Through a scientific approach anchored in proprietary technology, Keros navigates the intricate pathways of cellular growth and differentiation, thereby developing therapeutics with the potential to significantly improve patients' quality of life. Their pipeline, headlined by lead product candidates like KER-050 and KER-047, targets conditions such as myelodysplastic syndromes and fibrodysplasia ossificans progressiva, conditions that have long posed challenges to traditional medical interventions. Keros Therapeutics generates revenue primarily through the development and potential commercialization of its targeted therapies. By advancing their candidates through various clinical trial phases, Keros seeks to unlock significant market opportunities in sectors characterized by high demand and limited treatment options. Partnerships and strategic collaborations further bolster their financial backbone, as these relationships often bring in milestone payments and future royalty arrangements. The company’s model is one of strategic innovation—leveraging cutting-edge science to address critical health issues while carving out a competitive niche in the biotechnology market. This robust approach not only fuels potential breakthroughs but also charts a sustainable path toward profitability in an industry where the aspirations to alleviate complex medical conditions align seamlessly with business growth potentials.
See Also
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Based on Keros Therapeutics Inc's most recent financial statements, the company has Operating Margin of -5 939%.
You don't have any saved screeners yet